New Drug for Rare Autoimmune Diseases Secures 300 Billion Won Funding Following Successful Phase 3 Trials in the U.S.

Zenas BioPharma, Inc. (ZBIO) announced in its Q4 and full-year 2025 earnings release that its lead pipeline candidate, obexelimab—targeting the rare autoimmune IgG4-related disease—achieved positive results in the Phase 3 INDIGO trial, and that the company plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration in the second quarter of 2026.

The company also said it will file for approval with the European Medicines Agency in the second half of 2026 for the same therapy, expects to report topline data from its Phase 2 SunStone study in systemic lupus erythematosus (SLE) in the fourth quarter of 2026, and intends to advance clinical development of additional pipeline candidates including ZB014, orelabrutinib, ZB021 and ZB022.

In addition, Zenas BioPharma secured commercialization and R&D funding by entering into a five-year, secured multi-tranche loan agreement of up to $250 million (approximately KRW 330 billion) with a PhamaCon Advisors-managed fund. Despite a substantial increase in operating expenses and net loss in 2025, the company projects a cash runway through 2027, contingent on the receipt of further milestone payments.

On March 27, the company confirmed the pricing of concurrent public offerings of $200 million in 2.50% convertible senior notes and 5 million shares of common stock at $20 per share, aiming to raise approximately $280 million (about KRW 360 billion) to fund autoimmune disease therapy development and commercialization. These offerings are expected to close on March 31.

On the same day, insider Hongbo Lu disclosed that, through a NextBio-affiliated fund, he purchased approximately 75,000 shares of common stock at $20 per share in the offering, representing an indirect stake increase valued at $1.5 million (about KRW 2 billion).

Headquartered in Massachusetts, Zenas BioPharma is a clinical-stage global biotech company focused on developing therapies for autoimmune diseases. Its dual-function, B-cell-targeting monoclonal antibody obexelimab is being evaluated across indications including IgG4-related disease, multiple sclerosis and SLE.

The rare autoimmune and immunological disease treatment market offers significant growth potential driven by unmet medical needs and premium pricing. However, it is highly competitive, with global big pharma and numerous biotech players competing for clinical success and large-scale financing—factors that ultimately drive company valuations and share performance.